Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
Robert Harrington, Patricia Harkins, Richard Conway
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6690-6690
Open Access | Times Cited: 21

Showing 21 citing articles:

Advances in Synthetic Immunology for Targeted Treatment of Systemic Autoimmune Diseases: Opportunities, Challenges, and Future Directions
Galih Januar Adytia, Henry Sutanto, Laras Pratiwi, et al.
Immuno (2025) Vol. 5, Iss. 1, pp. 6-6
Open Access | Times Cited: 2
Emerging strategies for nanomedicine in autoimmunity
Ajay S. Thatte, Margaret M. Billingsley, Drew Weissman, et al.
Advanced Drug Delivery Reviews (2024) Vol. 207, pp. 115194-115194
Closed Access | Times Cited: 10
Mortality and Medical Utilization in Rheumatoid Arthritis Associated Interstitial Lung Disease: A Real-World, Large-Scale Retrospective Study Comparing Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors.
Po‐Cheng Shih, Qinghua Zou, Chih-Cheng Lai, et al.
Seminars in Arthritis and Rheumatism (2025) Vol. 71, pp. 152636-152636
Closed Access | Times Cited: 1
Palmoplantar plaque psoriasis responsive to upadacitinib: A report of two cases
Bohmyi Choi, Heidi Oi‐Yee Li, Steven J. Glassman
SAGE Open Medical Case Reports (2025) Vol. 13
Open Access | Times Cited: 1
A critical evaluation of nemolizumab for prurigo nodularis
Sarah G Brooks, Gil Yosipovitch
Expert Review of Clinical Immunology (2024) Vol. 20, Iss. 6, pp. 577-587
Closed Access | Times Cited: 5
Remote-Customized Telecontrol for Patients with Rheumatoid Arthritis: The iARPlus (Innovative Approach in Rheumatology) Initiative
Fausto Salaffi, Sonia Farah, Eleonora Di Donato, et al.
Journal of Personalized Medicine (2025) Vol. 15, Iss. 1, pp. 30-30
Open Access
A Review of the Impact of Sjögren’s Syndrome and/or the Presence of Anti-Ro/SS-A Antibodies on Therapeutic Strategies for Rheumatoid Arthritis
Yoshiro Horai, Shota Kurushima, Toshimasa Shimizu, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 568-568
Open Access
A theoretical approach to the possibility of applying the C19Al, C19B, C19N, C19Si, and C20 fullerene as well as the g-B3N4, g-C3N4, and g-Si3P4 nanosheets as carriers for drug delivery (and sensors for detection of the residue) of the Janus kinase inhibitor tofacitinib
Seyyed Amir Siadati, Mohammad Ali Ebrahimzadeh, Esmaeil Babanezhad, et al.
Chemistry of Heterocyclic Compounds (2025)
Closed Access
A practical approach to positioning therapies in ulcerative colitis
Russell Yanofsky, David T. Rubin
Journal of the Canadian Association of Gastroenterology (2025) Vol. 8, Iss. Supplement_2, pp. S6-S14
Open Access
Physiologically Based Pharmacokinetic Modeling of Tofacitinib: Predicting Drug Exposure and Optimizing Dosage in Special Populations and Drug–Drug Interaction Scenarios
Zhihai Cao, Zilong Wang, Qian Zhang, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 425-425
Open Access
T cell dysregulation in rheumatoid arthritis: Recent advances and natural product interventions
Mingyue Hu, Yujun Zhou, Zhongliu Yao, et al.
International Immunopharmacology (2025) Vol. 153, pp. 114499-114499
Closed Access
A Consensus Report by the RAPID-India Group on Optimising Tofacitinib Treatment for Indian Patients with Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis
de Bisschop G, Oak Jyotsna, Uma Kumar, et al.
Indian Journal of Rheumatology (2025)
Open Access
Natural polysaccharide-based nanodrug delivery systems for targeted treatment of rheumatoid arthritis: A review
Devesh Kumar, Shubham Pandey, Brijesh Shivhare, et al.
International Journal of Biological Macromolecules (2025), pp. 143408-143408
Closed Access
Recent advances in nanocrystals for arthritis drug delivery
Luca Morici, Olivier Jordan, Éric Allémann, et al.
Expert Opinion on Drug Delivery (2025)
Open Access
Immunomodulatory interactions between mesenchymal stromal/stem cells and immune cells in psoriasis: therapeutic potential and challenges
Mohammadreza Dashti, Mojgan Mohammadi, Sajad Dehnavi, et al.
Stem Cell Research & Therapy (2025) Vol. 16, Iss. 1
Open Access
Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases
Robert Roskoski
Pharmacological Research (2023) Vol. 199, pp. 107036-107036
Open Access | Times Cited: 9
Revealing the changes in signaling pathways caused by tofacitinib in patients with rheumatoid arthritis through RNA sequencing and the correlation with clinical parameters
Fangyi Lu, Qilin Chen, Xin Qi, et al.
Clinical Rheumatology (2024) Vol. 43, Iss. 5, pp. 1479-1489
Closed Access | Times Cited: 1
Efficacy of Janus Kinase Inhibitors (JAK) in Combination with Methotrexate for Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Nashwa Essam Dyab, Areej Alkhalil Al Hurh, Aya Mudar Knifaty, et al.
Scholars Bulletin (2024) Vol. 10, Iss. 07, pp. 174-185
Open Access | Times Cited: 1
Use of Upadacitinib to Treat a Severe Flare-Up of Rheumatoid Arthritis During Anti-PD-1 Immune Checkpoint Inhibitor Therapy for Stage IV Squamous Cell Carcinoma of the Lung
Shunsuke Mori, Kazuyoshi Nakamura, Mitsuyo Shimamura, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 20, pp. 6257-6257
Open Access | Times Cited: 1
Global RA treatment recommendations: An update from the various international societies
Charles Cubberley, Ajesh B. Maharaj
Best Practice & Research Clinical Rheumatology (2024), pp. 102019-102019
Open Access | Times Cited: 1
Latest Treatment Perspectives for IBD-related Arthritis - a review
Michał Sęk, Olgerd Duchnevič, Iwona Galasińska, et al.
Journal of Education Health and Sport (2024) Vol. 61, pp. 55-72
Open Access
The cardiovascular risk of JAK inhibitors in treating rheumatic diseases
Alexander Kwan, Elvina Ingrid, Matthew Jiang, et al.
International Journal of Rheumatic Diseases (2024) Vol. 27, Iss. 8
Closed Access
Janus kinase inhibitors versus tumor necrosis factor inhibitors in rheumatoid arthritis: meta-analytical comparison of efficacy and safety
Mahmoud Kandeel, Mohamed A. Morsy, Khalid M. Alkhodair, et al.
Inflammopharmacology (2024) Vol. 32, Iss. 5, pp. 3229-3246
Closed Access
Page 1

Scroll to top